Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis

• Published in: PloS one Vol. 15; no. 1; p. e0227138
• Main Authors: Yakhelef, Nadia, Audibert, Martine, Ferlazzo, Gabriella, Sitienei, Joseph, Wanjala, Steve, Varaine, Francis, Bonnet, Maryline, Huerga, Helena
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30.01.2020; Public Library of Science (PLoS)
• Subjects: Adult; Algorithms; Biology and Life Sciences; Biomarkers - urine; CD4 antigen; Comparative analysis; Cost analysis; Cost benefit analysis; Death; Decision analysis; Diagnosis; Diagnostic systems; Disabilities; Economic aspects; Ethics; Female; HIV; HIV Infections - complications; HIV patients; Human health and pathology; Human immunodeficiency virus; Humans; Infectious diseases; Interest rates; Laboratories; Life Sciences; Lipopolysaccharides - urine; Male; Medical diagnosis; Medical research; Medicine and Health Sciences; Microscopy; Molecular Diagnostic Techniques - economics; Physical Sciences; Research and Analysis Methods; Social Sciences; Sputum; Studies; Tuberculosis; Tuberculosis - diagnosis; Tuberculosis - urine; Urine; Kenya; South Africa; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0227138

Tuberculosis (TB) is the leading cause of death among HIV-positive patients. We assessed the cost-effectiveness of including lateral-flow urine lipoarabinomannan (LF-LAM) in TB diagnostic algorithms for severely ill or immunosuppressed HIV-positive patients with symptoms of TB in Kenya. From a decision-analysis tree, ten diagnostic algorithms were elaborated and compared. All algorithms included clinical exam. The costs of each algorithm were calculated using a 'micro-costing' method. The efficacy was estimated through a prospective study that included severely ill or immunosuppressed (CD4<200cells/μL) HIV-positive adults with symptoms of TB. The cost-effectiveness analysis was performed using the disability-adjusted life year (DALY) averted as effectiveness outcome. A 4% discount rate was applied. The algorithm that added LF-LAM alone to the clinical exam lead to the least average cost per TB case detected (€47) and was the most cost-effective with a cost/DALY averted of €4.6. The algorithms including LF-LAM, microscopy and X-ray, and LF-LAM and Xpert in sputum, detected a high number of TB cases with a cost/DALY averted of €6.1 for each of them. In the comparisons of the algorithms two by two, using LF-LAM instead of microscopy (clinic&LAM vs clinic&microscopy) and using LF-LAM along with GeneXpert in sputum instead of GeneXpert in urine along with GeneXpert in sputum, (clinic&LAM&Xpert_sputum vs clinic&Xpert_sputum&Xpert_urine) led to the highest increase in the cost-effectiveness ratios (ICERs): €-7.2 and €-12.6 respectively. In these two comparisons, using LF-LAM increased the number of TB patients detected while reducing costs. Adding LF-LAM to smear microscopy alone or to smear microscopy and Xray led to the highest increase in the additional number of TB cases detected (31 and 25 respectively) with an incremental efficiency estimated at 134 and 344 DALYs respectively. The ICERs were €22.0 and €8.6 respectively. Including LF-LAM in TB diagnostic algorithms is cost-effective for severely ill or immunosuppressed HIV-positive patients.